Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC-Reference-Cited by-同舟云学术

Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC

Published:2021-08 Issue: Volume: Page:100787
ISSN:0147-0272
Container-title:Current Problems in Cancer
language:en
Short-container-title:Current Problems in Cancer

Author:

Rossi Sabrina^ORCID,Damiano Paola,Toschi Luca,Finocchiaro Giovanna,Giordano Laura,Marinello Arianna^ORCID,Bria Emilio,D'Argento Ettore,Santoro Armando

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J. Thorac. Oncol.,2014

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802);Zhou;Ann. Oncol.,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review;Journal of Thoracic Oncology;2024-07

2. Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review;Frontiers in Pharmacology;2023-08-29

3. Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study;Cancer Science;2023-03-12

4. EGFR-Directed Therapy in Lung Cancer;El in Molecular Onco;2023-01-05

5. Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review);Oncology Letters;2022-09-26